Stacking GLP-1 agonists with other appetite suppressants like phentermine increases side effect risk without clear additive benefit
Your BHRC physician will provide specific dosing instructions based on your individual protocol
When administering the lower dose of Semaglutide at 1 mg to treat patients with diabetes, the SUSTAIN study consistently demonstrated significant improvements in glucose control and body weight reduction 29,30,31,32,33,34,35
You can learn more at LiperaHealth
Potential risks include changes in growth hormones, abnormal tissue growth, or interference with Tissue Regeneration pathways
This can affect how you metabolize medications and utilize nutrients